1. Home
  2. TYRA vs CLMT Comparison

TYRA vs CLMT Comparison

Compare TYRA & CLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$33.74

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Calumet Specialty Products Partners L.P.

CLMT

Calumet Specialty Products Partners L.P.

HOLD

Current Price

$31.87

Market Cap

2.1B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
CLMT
Founded
2018
1916
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
TYRA
CLMT
Price
$33.74
$31.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$47.50
$28.65
AVG Volume (30 Days)
749.1K
848.8K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
85.39
EPS
N/A
N/A
Revenue
N/A
$4,137,100,000.00
Revenue This Year
N/A
$3.94
Revenue Next Year
N/A
$1.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.75
$12.70
52 Week High
$40.65
$36.94

Technical Indicators

Market Signals
Indicator
TYRA
CLMT
Relative Strength Index (RSI) 43.61 47.31
Support Level $33.29 $29.81
Resistance Level $33.99 $33.27
Average True Range (ATR) 1.98 1.44
MACD -0.02 -0.21
Stochastic Oscillator 30.44 18.58

Price Performance

Historical Comparison
TYRA
CLMT

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About CLMT Calumet Specialty Products Partners L.P.

Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.

Share on Social Networks: